Stay updated on Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Sign up to get notified when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.

Latest updates to the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page
- Check7 days agoChange DetectedThe change consists of Revision: v3.4.2 replacing v3.4.1, which appears to be a metadata/version update without altering study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check14 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check21 days agoChange DetectedAdded a glossary section; updated capitalization of labels such as 'Last Update Submitted that Met QC Criteria' and the FEAR Act notice, and updated the site revision to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check36 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check57 days agoChange DetectedA Locations section has been added listing Texas and Utah sites; the separate Texas Locations and Utah Locations pages have been removed, and the revision is updated to v3.3.3.SummaryDifference0.3%

- Check86 days agoChange DetectedThe page shows a revision update from v3.2.0 to v3.3.2; there are no visible changes to study details, eligibility criteria, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.